(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.05%.
Eledon Pharmaceuticals's earnings in 2026 is -$99,910,000.On average, 7 Wall Street analysts forecast ELDN's earnings for 2026 to be -$78,742,056, with the lowest ELDN earnings forecast at -$82,821,366, and the highest ELDN earnings forecast at -$65,699,641. On average, 6 Wall Street analysts forecast ELDN's earnings for 2027 to be -$68,795,691, with the lowest ELDN earnings forecast at -$80,432,288, and the highest ELDN earnings forecast at -$57,167,220.
In 2028, ELDN is forecast to generate -$71,493,562 in earnings, with the lowest earnings forecast at -$88,395,881 and the highest earnings forecast at -$58,020,463.